Join us in Advancing the Mission of ASGCT

asgct.org
American Society of Gene & Cell Therapy

Mission and Vision

The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease.

ASGCT’s strategic vision is to be a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

History

ASGCT was established in 1996 by Dr. George Stamatoyannopoulos, professor of medicine at the University of Washington’s School of Medicine, and a group of the country’s leading researchers in gene therapy.

5,600+ Members

ASGCT is the primary professional membership organization for gene and cell therapy. The Society’s members are scientists, physicians, patient advocates, and other professionals. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, and biotechnology and pharmaceutical companies.

Become a member today!

Board of Directors and Officers

ASGCT’s Board of Directors and committee members are the life blood of the Society, dedicated to shaping ASGCT and determining the Society’s programs.

Volunteer to serve on a committee.

Lear more about ASGCT’s history.
ASGCT Year-Round

Impactful Resources
- Molecular Therapy Family of Journals
- Patient Education
- Landscape Reports
- ASGCT News

Engaging Education
- Annual Meeting
- Policy Summit
- Virtual Events and Webinars

Advancing the Field
- Grants & Awards
- Career Center
- Advocacy
The Premeire Annual Meeting in the Field

Cutting edge science and crucial connections propelling the field forward

Join over 7,600 professionals in gene & cell therapy to learn about new technologies and developments in the field, and create and strengthen powerful partnerships

- Nearly 200 hours of programming
- 153 Speakers
- 336 Abstract Presenters
- 896 Posters
- 170+ Exhibitors

Exhibit and Sponsor at the 26th Annual Meeting
Nearly $1 Million in Career Development & DEI Award Funding

Underrepresented Minority Fellowship Awards in Gene and Cell Therapy
Two $100,000 fellowships will support ASGCT members in a postdoctoral or early-stage investigator fellowship in gene or cell therapy-related research. One award will be given specifically for an oncology indication and the other for any indication within gene and cell therapy.

Award for Research on Conditions Disproportionately Affecting Minorities
One $50,000 award will support an ASGCT member in gene or cell therapy-related research for conditions disproportionately affecting minorities for one year.

Career Development Awards for Early Professionals
Six recipients will receive $100,000, totaling $600,000 in funding across the categories below:

- Viral Vector Development
- Gene Targeting and Gene Correction
- Oligonucleotide Therapeutics
- Synthetic/Molecular Conjugates and Physical Methods for Delivery of Gene Therapeutics
- Cell Therapies
- Immunological Aspects of Gene Therapy and Vaccines

asgct.org/awards
Patient & Public Education
Your go-to Trusted Source

Our award winning Patient Education resources are developed by the ASGCT Patient Outreach Committee in coordination with patient advocacy groups and other critical stakeholders. We strive to develop accurate, reliable, and accessible resources about gene and cell therapies available to patients and the public.

30+ Educational Videos with over 550,000 views!
Gene therapy 101, disease treatments, the patient journey, clinical trials, and more

Live Lunch and Learn webinars with over 8,300 on-demand views since launched in early 2022

Clinical Trials Finder
An interactive database of all active and recruiting gene & cell therapy clinical trials around the world
Policy and Advocacy

New science requires new solutions

The Society works to advance the field by advocating for policies in the areas of FDA regulation, patient access, research funding, and genetic screening and testing. The Policy Summit provides educational programming that connects policy and industry thought leaders with corporate, government relations, market access, regulatory, and scientific professionals.

FDA/Regulatory Policy
Improve CBER resourcing, early communications (INTERACT meetings), CMC review, and platform regulation

Medicaid Policy
Increase access to cell and gene therapies for individuals covered by Medicaid, with a focus on the pipeline and the need for proactive solutions now

Access & Reimbursement of Gene Therapies
Increase provider reimbursement for new gene and cell therapies, correct disparate reimbursement based on site of service, and improve access to products (agnostic to payor)

Genetic Testing & Screening
Support broader adoption of RUSP conditions in states, accelerate adoption of new conditions onto the RUSP, enable providers to use whole genome sequencing where appropriate to diagnose rare diseases more rapidly

Research Funding
Increase funding for gene and cell therapy research through NIH and ARPA-H

Support Policy & Advocacy

2022 Policy Summit Agenda
2021 Policy Summit Agenda
Educational Webinars & Virtual Events

Insight Series
You don’t need to wait for the Annual Meeting to get the latest research and insights. The Insight Series dives into cutting-edge topics presented by gene and cell therapy experts. Sponsorships opportunities coming soon.

Professional Development Cafés
These monthly two-hour webinars provide up-to-date, high-quality education focused for early-career professionals. Advertising opportunities available.

Global Outreach
ASGCT will expand its mission outside of the United States, increasing membership, offering programming, and promoting access throughout the world. Sponsorship opportunities coming soon.

Lunch & Learns
These webinars provide an avenue for patient advocates, physicians, and other professionals in the gene and cell therapy field to come together to learn and discuss important educational topics. Sponsorships available.
Advertisement Opportunities

Reach your Target Audience

WHO ARE ASGCT’S 5,600+ MEMBERS?*

<table>
<thead>
<tr>
<th>Institution Type</th>
<th>% of</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Profit</td>
<td>3%</td>
</tr>
<tr>
<td>Industry, Corporate</td>
<td>57%</td>
</tr>
<tr>
<td>Government</td>
<td>1.5%</td>
</tr>
<tr>
<td>Other</td>
<td>2.25%</td>
</tr>
<tr>
<td>Academic</td>
<td>36%</td>
</tr>
</tbody>
</table>

5,000+ Recipients
26.8% Average Open Rate
9.1% Average Click-to-Open Rate

The Vector

1,200+ Recipients
27.7% Average Open Rate
10.1% Average Click-to-Open Rate

The Advocate

5,000+ Recipients
34.2% Average Open Rate
7.3% Average Click-to-Open Rate

Going Viral

Approximately 15% of members live outside of the United States.

Membership is Global

Professional Development Café Series

Up to 1,000 views

*Please note: respondents could only select one function. Other responses <1%.
Let’s Connect

development@asgct.org
year-round sponsorships, donations, and development

exhibits@asgct.org
annual Meeting exhibit and sponsorship inquiries

advertising@asgct.org
advertising opportunities

Facebook
www.facebook.com/ASGCTherapy

Twitter
@ASGCTherapy

Instagram
www.instagram.com/asgctherapy

LinkedIn
American Society of Gene and Cell Therapy

Website
www.asgct.org